MA
MANE

Montag & Associates’s Veradermics Inc MANE Stock Holding History

Montag & Associates’s Portfolio MANE Stock Details MANE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454 Buy
+4
New +$375 ﹤0.01% 947

Other funds holding MANE

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Montag & Associates's MANE Position: Q2 2026 in Review

Montag & Associates opened a new position in Veradermics Inc (MANE) in Q2 2026: 4 shares worth $454. The stake represents ﹤0.01% of the portfolio and ranks #947 among its holdings.

148 funds tracked by Wall St. Rank hold MANE as of Q2 2026.

  • Montag & Associates held 4 shares of Veradermics Inc worth $454 as of Q2 2026.
  • Veradermics Inc was a new Montag & Associates position in Q2 2026.
  • Veradermics Inc made up ﹤0.01% of Montag & Associates's portfolio in Q2 2026, its #947 holding.
  • 148 funds tracked by Wall St. Rank held Veradermics Inc as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.